As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries.

EDUFLUVAC aims to develop an influenza vaccine that educates the immune system to recognise common influenza epitopes, using a combination of influenza haemagglutinin (HA) antigens delivered on a single virus-like particle. The knowledge generated will provide Proof of Principle in relevant animal models for an influenza vaccine that does not have to be updated annually, does not have to be manufactured on an annual basis and will not require an annual vaccination campaign. It will also provide for an economically viable large scale production platform for influenza vaccine which, in the event of a pandemic, can manufacture rapidly high quantities of vaccine. All industrial partners (including two SMEs) will benefit from the compilation of the regulatory dossier for transfer to larger vaccine companies and the deeper knowledge integration emanating from EDUFLUVAC in a 2.8 billion global annual influenza vaccine market.

About CVIs EDUFLUVAC partners:

European Vaccine Initiative

The European Vaccine Initiative (EVI; European Malaria Vaccine Initiative, EMVI, until 2009) is a leading European non-profit Product Development Partnership that has the principal objective to develop effective, accessible, and affordable vaccines against diseases of poverty. Since its inception in 1998 it has contributed to the development of 32 vaccine candidate formulations with 15 vaccine candidates being advanced into phase I clinical trials, three of which have been transitioned to partner organisations for further clinical development. EVI is hosted by Heidelberg University, Germany.


Redbiotec AG (RBT) is a privately Swiss Biopharmaceutical Company, based in Zurich-Schlieren. At the core of RBT lies the rePAX® co-expression technology platform for the efficient generation of recombinant multi-component virus-like particles (reVLPs®) and other protein assemblies for vaccine development and display of membrane proteins for therapeutic antibody development.

iBET – Instituto de Biologia Experimental e Tecnológica

The Instituto de Biologia Experimental e Tecnológia (iBET) is a private not for profit research organisation created in 1989, acting as an interface between academic and industry research. iBET brings together, as partners and collaborators, private companies and public institutions, organising competences for product and process development. iBET know-how in terms of biopharmaceuticals spans from the initial expression vector design and cell line establishment through all stages of process development and scale-up (production, purification, stability and storage). Currently iBET collaborates with over 40 European and USA companies.


Etna Biotech S.r.l. is a Research Centre headquartered in Catania, Italy. Start up of the former Swiss Serum and Vaccine Institute, later Berna Biotech, Etna Biotech is a company whose key competencies lie in researching and developing vaccines and immunotherapeutics for infectious diseases and other chronic illnesses. Etna Biotech has been acquired in 2008 by the Zydus International Ltd a Zydus Cadila Company. Zydus Cadila is an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products.

Biomedical Primate Research Centre

The Biomedical Primate Research Centre (BPRC) is a not for profit research foundation, with a strong background in vaccine development. BPRC investigators have pioneered key steps in the development of malaria, HIV, Hepatitis C, West Nile virus and Tuberculosis vaccine candidates. BPRC is committed to using non-human primates for this critical research only when there are no suitable alternatives. The non-human primate facilities at BPRC allow challenge studies with pathogens up to BSL3plus level. BPRC offers state of the art immunological expertise and animal facilities (AAALAC accredited) and is fully compliant with regulations on the use of non-human primates for medical research.

National Institute for Biological Standards and Control

The National Institute for Biological Standards and Control (NIBSC) -a centre of the Medicine and Healthcare Product Regulatory Agency- is operating at the interface between cutting edge scientific research, biopharmaceutical quality control and government regulation, and has recently merged with MHRA (UK National Regulatory Authority) in 2013. It is the global leader in the field of biological standardisation, responsible for developing and producing over 90% of the International Standards in use around the world to assure the quality of biological medicines. The NIBSC also plays an important role as one of the four World Health Organization (WHO) Essential Regulatory Laboratories for influenza vaccines.